Chairs:
Robert Chen
Toronto, ON, Canada
Marina AJ de Koning-Tijssen
Amsterdam, Netherlands

The clinical features of myoclonus
Philip Thompson
Adelaide, Australia

The neurophysiology of myoclonus: Asking the right question
Robert Chen
Toronto, ON, Canada

How to treat myoclonus and hyperekplexias
Marina de Koning-Tijssen
Amsterdam, Netherlands

At the conclusion of this session, participants should be better able to:

1. Recognize the clinical features of different forms of myoclonus including hyperekplexias
2. Understand the basic neurophysiology of myoclonus
3. Discuss strategies for treating myoclonus

Chairs:
Bob van Hilten
Leiden, Netherlands
Pablo Martínez-Martín
Madrid, Spain

The spectrum of non-motor symptoms in Parkinson's disease
Charles Adler
Scottsdale, AZ, USA

Sleep, sleepiness and nocturnal complaints in Parkinson's disease
Isabelle Arnulf
Paris, France

Pain, constipation and orthostatic hypotension in Parkinson's disease: Basic strategies for therapy
K. Ray Chaudhuri
London, United Kingdom

At the conclusion of this session, participants should be better able to:

1. Understand the frequency and relevance of non-motor symptoms in PD and their impact on quality of life
2. Learn the diagnostic tools available for detecting and quantifying non-motor symptoms in PD
3. List the available treatments for sleep, pain and autonomic dysfunction in PD

Chairs:
Janis Miyasaki
Toronto, ON, Canada
Daniel Weintraub
Philadelphia, PA, USA

The clinical spectrum of ICDs and dopamine dysregulation syndrome (DDS)
Mark Stacy
Durham, NC, USA

How to detect ICDs in Parkinson's disease
Daniel Weintraub
Philadelphia, PA, USA

How to manage ICDs in Parkinson's disease
Andrew Evans
Parkville, Australia

At the conclusion of this session, participants should be better able to:

1. Discuss the relationship between ICDs and dopamine dysregulation syndrome (DDS) in PD
2. Identify behaviors suggestive of ICD and DDS
3. Describe the management of ICD and DDS

Chairs:
Charles Adler
Scottsdale, AZ, USA
Keith Josephs
Rochester, NY, USA

Understanding tau-protein dysfunction and pathways to curative
Rohan de Silva
London, United Kingdom

The anatomical source of the signs and symptoms of Parkinson's disease
Maria Rodriguez-Oroz
Pamplona, Spain

Current concepts of dyskinesias, and new therapeutic strategies
M. Angela Cenci
Lund, Sweden

At the conclusion of this session, participants should be better able to:

1. Understand the role of tau protein dysfunction in neurodegeneration and potential treatment strategies
2. Understand biological models of dyskinesias and insights they give to therapeutic
3. Discuss clinical and pathological correlations in Parkinson's disease through an understanding selective regional vulnerability to Lewy body pathology

Chairs:
Caroline Tanner
Sunnyvale, CA, USA
Louis Tan
Singapore

A frequent question: The role of smoking, caffeine and nutrition in Parkinson's disease
Louis Tan
Singapore

Toxin induced parkinsonism: The manganese cases
Pille Taba
Tartu, Estonia

Herbicides and pesticides in Parkinson's disease
Caroline Tanner
Sunnyvale, CA, USA

At the conclusion of this session, participants should be better able to:

1. Understand the role of environmental factors in Parkinson's disease
2. Recognize the clinical features of toxin-induced parkinsonism
3. Describe the possible effects of pesticides in Parkinson's disease

Chairs:
Anette Schrag
London, United Kingdom
Christopher Goetz
Chicago, IL, USA

Similarities and differences between the MDS-UPDRS and the original UPDRS
Anette Schrag
London, United Kingdom

Key characteristics of the MDS-UPDRS with emphasis on difficult items
Glenn Stebbins
Chicago, IL, USA

Application of the MDS-UPDRS
Pablo Martínez-Martín
Madrid, Spain

At the conclusion of this session, participants should be better able to:

1. Identify similarities and differences between the MDS-UPDRS and the original UPDRS
2. Evaluate key characteristics of the MDS-UPDRS with emphasis on difficult items
3. Develop the capability to apply the MDS-UPDRS

Chairs:
Daniel Tarsy
Boston, MA, USA
Kathleen Shannon
Chicago, IL, USA

Approach to chorea, athetosis and ballism
Kathleen Shannon
Chicago, IL, USA

Management of Huntington's disease
Roberto Weiser
Caracas, Venezuela

Updates on Huntington's disease-like diseases (HDL-1, HDL2, DRPLA, SCA 17, etc.)
Vitor Tumas
Ribeirão Preto, Brazil

At the conclusion of this session, participants should be better able to:

1. Understand how to approach patients with chorea, athetosis and ballism
2. Be able to manage patients with Huntington's disease
3. Learn the latest in the field of HD-like diseases

Chairs:
Bastiaan Bloem
Nijmegen, Netherlands
Nir Giladi
Tel Aviv, Israel

Gait disorders: Features and differential diagnosis
Bastiaan Bloem
Nijmegen, Netherlands

Gait issues in normal pressure hydrocephalus and vascular parkinsonism: Diagnosis, neuroimaging, and management
Amos Korczyn
Ramat Aviv, Israel

Physical therapy in gait disorders -evidence based?
Quincy Almeida
Waterloo, ON, Canada

At the conclusion of this session, participants should be better able to:

1. Understand how to approach, classify and evaluate gait disorders
2. Comprehend what frontal gait disorders are
3. Be able to manage patients with gait disorders through medical and rehabilitation strategies